Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.43 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 4/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13702213 | 0.88 | ALDH1A1 (0.43) | PRKCAPRKCDALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL4078739 | 0.88 | MAPK1 (0.48) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL13901188 | 0.84 | CYP1A2 (0.44) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL13702237 | 0.83 | L3MBTL1 (0.37) | PRKCAPRKCDALDH1A1TLR2MAPK1 | |
| SCHEMBL4255720 | 0.82 | ALDH1A1 (0.54) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL14216668 | 0.81 | ALDH1A1 (0.67) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL18759378 | 0.81 | ALDH1A1 (0.67) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| Hydrochloric Acid SCHEMBL6839365 | 0.80 | ALDH1A1 (0.65) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| Iodide SCHEMBL1685005 | 0.80 | ALDH1A1 (0.65) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL19300948 | 0.79 | ALDH1A1 (0.68) | PRKCAPRKCEPRKCQPRKCDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221684-A1 | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2007073489-A2 | MOLECULES FOR GENE DELIVERY AND GENE THERAPY, AND METHODS OF USE THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221684-A1 | Molecules for Gene Delivery and Gene Therapy, and Methods of Use Thereof | ANXA6, STING1, ADM2 | PRKCA 3834/4885PRKCE 3795/4885PRKCQ 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.